We introduce ourselves as one of the most prominent organizations to offer Bicalutamide Tablets USP 50mg which is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate. Our entire range is utilized to treat prostate cancer that has spread to other areas of the body. These Bicalutamide Tablets USP 50mg are tested by a team of experts on different stages to deliver the defect-free range to the customers.
Main Export Market(s)
Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa
"We are inviting inquiries only from South America, Africa, Middle East, Cih, South East Asia."
Disclaimer: Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities.
FLAGSHIP BIOTECH INTERNATIONAL PVT. LTD.
1302, Rupa Solitaire, Millenium Business Park (MBP), Next to Hotel Ramada, Mahape, Navi Mumbai - 400710, Maharashtra, India